The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Potential Mechanism for Sustained Antiretroviral Efficacy of AZT-3TC Combination Therapy
Abstract
Combinations of antiretroviral drugs that prevent or delay the appearance of drug-resistant human immunodeficiency virus-type 1 (HIV-1) mutants are urgently required. Mutants resistant to 3′-azidothymidine (AZT, zidovudine) became phenotypically sensitive in vitro by mutation of residue 184 of viral reverse transcriptase to valine, which also induced resistance to (-)2′-deoxy-3′-thiacytidine (3TC). Furthermore, AZT-3TC coresistance was not observed during extensive in vitro selection with both drugs. In vivo AZT-3TC combination therapy resulted in a markedly greater decrease in serum HIV-1 RNA concentrations than treatment with AZT alone, even though valine-184 mutants rapidly emerged. Most samples assessed from the combination group remained AZT sensitive at 24 weeks of therapy, consistent with in vitro mutation studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
Ho, D. D., Neumann, A. U., Perelson, A. S., Chen, W., Leonard, J. M., & Markowitz, M. (1995) · Nature · doi:10.1038/373123a0 · Cited by 4,267
Viral dynamics in human immunodeficiency virus type 1 infection
Wei, X., Ghosh, S. K., Taylor, M. E., Johnson, V. A., Emini, E. A., Deutsch, P., Lifson, J. D., Bonhoeffer, S., Nowak, M. A., Hahn, B. H., et al. (1995) · Nature · doi:10.1038/373117a0 · Cited by 3,260
HIV with Reduced Sensitivity to Zidovudine (AZT) Isolated During Prolonged Therapy
Larder, B. A., Darby, G., & Richman, D. D. (1989) · Science · doi:10.1126/science.2467383 · Cited by 1,559
Self-citationMultiple Mutations in HIV-1 Reverse Transcriptase Confer High-Level Resistance to Zidovudine (AZT)
Larder, B. A., & Kemp, S. D. (1989) · Science · doi:10.1126/science.2479983 · Cited by 1,163
Self-citationInfection of HTLV-III/LAV in HTLV-I-Carrying Cells MT-2 and MT-4 and Application in a Plaque Assay
Harada, S., Koyanagi, Y., & Yamamoto, N. (1985) · Science · doi:10.1126/science.2992081 · Cited by 857
Resistance to ddI and Sensitivity to AZT Induced by a Mutation in HIV-1 Reverse Transcriptase
St. Clair, M. H., Martin, J. L., Tudor-Williams, G., Bach, M. C., Vavro, C. L., King, D. M., Kellam, P., Kemp, S. D., & Larder, B. A. (1991) · Science · doi:10.1126/science.1716788 · Cited by 679
Self-citationTisdale, M., Kemp, S. D., Parry, N. R., & Larder, B. A. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.12.5653 · Cited by 603
Self-citationMulder, J., McKinney, N., Christopherson, C., Sninsky, J., Greenfield, L., & Kwok, S. (1994) · Journal of Clinical Microbiology · doi:10.1128/jcm.32.2.292-300.1994 · Cited by 558
Schuurman, R., Nijhuis, M., van Leeuwen, R., Schipper, P., de Jong, D., Collis, P., Danner, S. A., Mulder, J., Loveday, C., Christopherson, C., et al. (1995) · Journal of Infectious Diseases · doi:10.1093/infdis/171.6.1411 · Cited by 503
Kellam, P., Boucher, C. A., & Larder, B. A. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.5.1934 · Cited by 413
Self-citation
Cited by
Hammer, S. M., Squires, K. E., Hughes, M. D., Grimes, J. M., Demeter, L. M., Currier, J. S., Eron, J. J., Feinberg, J. E., Balfour, H. H., Deyton, L. R., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709113371101 · Cited by 2,640
Huang, H., Chopra, R., Verdine, G. L., & Harrison, S. C. (1998) · Science · doi:10.1126/science.282.5394.1669 · Cited by 1,420
Designed Multiple Ligands. An Emerging Drug Discovery Paradigm
Morphy, R., & Rankovic, Z. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058225d · Cited by 1,209
Analysis of drug combinations: current methodological landscape
Foucquier, J., & Guedj, M. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.149 · Cited by 1,115
“For these reasons, combination therapies have become a standard in several areas such as cancer (Humphrey et al. 2011), hypertension (Glass 2004), asthma (Nelson 2001), and AIDS (Larder et al. 1995; Oversteegen et al. 2007).”
BackgroundHammer, S. M., Katzenstein, D. A., Hughes, M. D., Gundacker, H., Schooley, R. T., Haubrich, R. H., Henry, W. K., Lederman, M. M., Phair, J. P., Niu, M., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610103351501 · Cited by 1,091
Gazzard, B., & on behalf of the BHIVA Treatment Guidelines Writing Group (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2008.00636.x · Cited by 1,089
Mechanisms of drug combinations: interaction and network perspectives
Jia, J., Zhu, F., Ma, X., Cao, Z. W., Li, Y. X., & Chen, Y. Z. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2683 · Cited by 969
HIV-1 Antiretroviral Drug Therapy
Arts, E. J., & Hazuda, D. J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a007161 · Cited by 851
Clavel, F., & Hance, A. J. (2004) · New England Journal of Medicine · doi:10.1056/nejm2ra025195 · Cited by 800
Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
Allen, M. I., Deslauriers, M., Andrews, W. C., Tipples, G. A., Walters, K.-A., Tyrrell, D. L., Brown, N., & Condreay, L. D. (1998) · Hepatology · doi:10.1002/hep.510270628 · Cited by 793
Multicomponent therapeutics for networked systems
Keith, C. T., Borisy, A. A., & Stockwell, B. R. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1609 · Cited by 769
Hirsch, M. S., Brun-Vézinet, F., D'Aquila, R. T., Hammer, S. M., Johnson, V. A., Kuritzkes, D. R., Loveday, C., Mellors, J. W., Clotet, B., Conway, B., et al. (2000) · JAMA · doi:10.1001/jama.283.18.2417 · Cited by 766
Virus dynamics and drug therapy
Bonhoeffer, S., May, R. M., Shaw, G. M., & Nowak, M. A. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6971 · Cited by 632
Hirsch, M. S., Conway, B., D'Aquila, R. T., Johnson, V. A., Brun-Vézinet, F., Clotet, B., Demeter, L. M., Hammer, S. M., Jacobsen, D. M., Kuritzkes, D. R., et al. (1998) · JAMA · doi:10.1001/jama.279.24.1984 · Cited by 563
Eron, J. J., Benoit, S. L., Jemsek, J., MacArthur, R. D., Santana, J., Quinn, J. B., Kuritzkes, D. R., Fallon, M. A., & Rubin, M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512213332502 · Cited by 531
Hirsch, M. S., Brun‐Vezinet, F., Clotet, B., Conway, B., Kuritzkes, D. R., D’Aquila, R. T., Demeter, L. M., Hammer, S. M., Johnson, V. A., Loveday, C., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/375597 · Cited by 514
Public Health Implications of Antiretroviral Therapy and HIV Drug Resistance
Wainberg, M. A. (1998) · JAMA · doi:10.1001/jama.279.24.1977 · Cited by 498
A robustness-based approach to systems-oriented drug design
Kitano, H. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2195 · Cited by 488
Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery
Zhu, F., Shi, Z., Qin, C., Tao, L., Liu, X., Xu, F., Zhang, L., Song, Y., Liu, X., Zhang, J., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr797 · Cited by 480
Back, N. K., Nijhuis, M., Keulen, W., Boucher, C. A., Oude Essink, B. O., van Kuilenburg, A. B., van Gennip, A. H., & Berkhout, B. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00777.x · Cited by 406
Toxicity of Antiviral Nucleoside Analogs and the Human Mitochondrial DNA Polymerase
Johnson, A. A., Ray, A. S., Hanes, J., Suo, Z., Colacino, J. M., Anderson, K. S., & Johnson, K. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106743200 · Cited by 403
Replicative Fitness of Protease Inhibitor-Resistant Mutants of Human Immunodeficiency Virus Type 1
Martinez-Picado, J., Savara, A. V., Sutton, L., & D’Aquila, R. T. (1999) · Journal of Virology · doi:10.1128/jvi.73.5.3744-3752.1999 · Cited by 396
Hertogs, K., de Béthune, M.-P., Miller, V., Ivens, T., Schel, P., Van Cauwenberge, A., Van den Eynde, C., van Gerwen, V., Azijn, H., van Houtte, M., et al. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.2.269 · Cited by 389
Self-citationDescamps, D. (2000) · JAMA · doi:10.1001/jama.283.2.205 · Cited by 367
Ding, J., Das, K., Hsiou, Y., Sarafianos, S. G., Clark, A. D., Jacobo-Molina, A., Tantillo, C., Hughes, S. H., & Arnold, E. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.2208 · Cited by 321
Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance
Shafer, R. W. (2002) · Clinical Microbiology Reviews · doi:10.1128/cmr.15.2.247-277.2002 · Cited by 314
Enhanced Fidelity of 3TC-Selected Mutant HIV-1 Reverse Transcriptase
Wainberg, M. A., Drosopoulos, W. C., Salomon, H., Hsu, M., Borkow, G., Parniak, M. A., Gu, Z., Song, Q., Manne, J., Islam, S., et al. (1996) · Science · doi:10.1126/science.271.5253.1282 · Cited by 304
Recent advances (2015–2016) in anticancer hybrids
Kerru, N., Singh, P., Koorbanally, N., Raj, R., & Kumar, V. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.033 · Cited by 295
Clinical Pharmacokinetics of Lamivudine
Johnson, M. A., Moore, K. H. P., Yuen, G. J., Bye, A., & Pakes, G. E. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936010-00004 · Cited by 275
Gregson, J., Rhee, S. Y., Datir, R., Pillay, D., Perno, C. F., Derache, A., Shafer, R. S., & Gupta, R. K. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz631 · Cited by 24
Mimtsoudis, I., Tsachouridou, O., Akinosoglou, K., & Metallidis, S. (2024) · Viruses · doi:10.3390/v16091392 · Cited by 13
“Furthermore, the mutation was confirmed to increase susceptibility to zidovudine (ZDV) [30] and, subsequently, stavudine (d4T) [31] and to tenofovir [32].”
Background
Metadata
- Authors
- Larder, B. A., Kemp, S. D., & Harrigan, P. R.
- Venue
- Science
- Published
- 1995-08-04
- Volume
- 269
- Issue
- 5224
- Pages
- 696-699
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2035938088
- Cited by
- 623
- References
- 24
- FWCI
- 54.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.